Dear all,

Please find today’s report below.

PHE’s COVID-19 Literature Digest has been produced since February 2020. A selection of our previous Digests can be found here. This resource aims to highlight a small selection of recent COVID-19 papers that are relevant to UK settings, contains new data / insights or emerging trends. The Digest team generate a report three times per week (Mon, Wed, Fri), which includes both preliminary reports of work (preprints) that have NOT been peer-reviewed and research that has been subject to peer review and wider scrutiny. The Digest is very rapidly produced and does not claim to be a perfect product; the inclusion or omission of a publication should not be viewed as an endorsement or rejection by PHE. We do not accept responsibility for the availability, reliability or content of the items included in this resource.

To join our email distribution list please send a request to COVID.LitDigest@phe.gov.uk. If you are interested in papers relating to behaviour and social science please contact COVID19.behaviouralscience@phe.gov.uk to sign up to receive the PHE Behavioural Sciences Weekly Report.

Best wishes,

Bláthnaid Mahon, Emma Farrow, James Robinson
On behalf of the PHE COVID-19 Literature Digest Team

Report for 26.10.2020 (please note that papers that have NOT been peer-reviewed are highlighted in red).

Sections:
- Serology and immunology
- Diagnostics
- Genomics
- Epidemiology and clinical – risk factors
- Epidemiology and clinical – other
- Infection control / non-pharmaceutical interventions
- Treatment
- Vaccine development
### Serology and immunology

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article Type</th>
<th>Digest</th>
</tr>
</thead>
</table>
  
  • Overall, 272 (12.1%) of individuals had at least one positive/equivocal spike protein IgG result, with the highest proportion in a hospital site (22%), 14% in London and 2.1% in a rural area. Results were similar for nucleoprotein IgG.  
  
  • Following a positive result, 39/587 (6.6%) tested negative for nucleoprotein IgG and 52/515 (10.1%) for spike protein IgG.  
  
  • Nucleoprotein IgG declined by 6.4% per week (95% CI, 5.5-7.4%; half-life, 75 [95% CI, 66-89] days) and spike protein IgG by 5.8% (95% CI, 5.1-6.6%; half-life, 83 [95% CI, 73-96] days). |
| 23.10.2020       | Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China | JAMA Netw Open / Research letter | • Seropositive prevalence was 3.9% in a cohort of 35,040 individuals in Wuhan, China. Adult participants aged 18 years or older were enrolled in the study. None of the participants had a history of COVID-19. Most tested positive for SARS-CoV-2 IgG antibodies only, indicating a prior infection.  
  
  • Seropositive prevalence: higher in urban districts than in suburban and rural areas, consistent with geographical distribution of confirmed cases; significantly higher among elderly individuals than in other age groups. |

### Diagnostics

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article Type</th>
<th>Digest</th>
</tr>
</thead>
</table>
| 21.10.2020       | Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing | medRxiv (non-peer reviewed) / Article | • Reports the viral RNA trajectories for 68 individuals using quantitative PCR testing.  
  
  • On average, symptomatic and asymptomatic individuals reached similar peak viral RNA concentrations (22.2 Ct, 95% credible interval [19.1, 25.1] vs. 22.4 Ct [20.2, 24.5]) within similar amounts of time (2.9 days [0.7, 4.7] vs. 3.0 days [1.3, 4.3]), but acute shedding lasted longer for symptomatic individuals (10.5 days [6.5, 14.0] vs. 6.7 days [3.2, 9.2]).  
  
  • A second test within 2 days after an initial positive PCR result reliably
indicated whether viral RNA concentration was increasing, decreasing, or in a low-level persistent phase.

### Genomics

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
<th>Digest</th>
</tr>
</thead>
<tbody>
<tr>
<td>23.10.2020</td>
<td>NERVTAG: Is there evidence for genetic change in SARS-CoV-2 and if so, do mutations affect virus phenotype? - 30 September 2020</td>
<td>Gov.uk / Research and analysis</td>
<td>• Concluded that there is no evidence that the limited number of genetic changes reported and investigated to date have brought about major shifts in viral tropism or virulence of SARS-CoV-2.</td>
</tr>
</tbody>
</table>

### Epidemiology and clinical – risk factors

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
<th>Digest</th>
</tr>
</thead>
</table>
| 23.10.2020       | Evaluation of excess mortality in European all-cause mortality data          | Gov.uk / Research and analysis    | • All-age, all-cause mortality data from 24 European countries for the period 2015-2020 was analysed using EuroMOMO Z-scores (number of standard deviations from expected mortality).
• Z-scores greater than four, signifying high excess mortality and reason for concern, were identified in 13/24 countries during 2020-H1.
• Maximum 2018-H1 mortality was positively correlated with 2020-H1 mortality, implying past high excess mortality predicts high 2020-H1 excess mortality.
• Lower per capita spending on healthcare, increased residential care and high previous excess mortality are significant predictors of countries with high 2020-H1 excess mortality. |
| 23.10.2020       | Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study | Clin Infect Dis / Accepted manuscript | • This paper was previously included in the Digest as a preprint.
• A study of 47,592 hospitalised COVID-19 patients to describe outcomes of HIV-positive patients (n=122) compared to HIV-negative.
• Mortality was higher among HIV-positive patients after adjusting for age (adjusted hazard ratio [aHR] 1.47, 95% confidence interval [CI] 1.01-2.14; p=0.05), and the association persisted after adjusting for the other variables (aHR 1.69; 95% CI 1.15-2.48; p=0.008) and when restricting the analysis to people aged <60 years (aHR 2.87; 95% CI 1.70-4.84; p<0.001). |
### Epidemiology and clinical — other

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
<th>Digest</th>
</tr>
</thead>
</table>
| 23.10.2020       | **COVID-19: time from symptom onset until death in UK hospitalised patients** | Gov.uk / Research and analysis | • In patients admitted to hospital with COVID-19, what is the time from symptom onset to death? Does this differ by age, sex, and first/second wave?  
• Patients were prospectively enrolled into the ISARIC-CCP-UK study (n = 76707). In those in whom symptom onset date was unknown, hospital admission date was used (7802 [9.8%]).  
• Median (interquartile range) of time from symptom onset to death is currently shorter in the second wave (7 days [IQR 11 days]) compared to the first wave (13 days [IQR 14 days]). However, it should be noted that insufficient time has elapsed since 1st Aug 2020 to provide sufficient follow-up for this and second-wave records are more incomplete.  
• Little difference is seen in time from hospital admission to death between first and second waves. |

| 21.10.2020       | **Mortality among Adults Ages 25-44 in the United States During the COVID-19 Pandemic** | medRxiv (non-peer reviewed) / Article | • Performed an observational cohort study using public data from the National Centre for Health Statistics at the US CDC and CDC Wonder. Analysed all-cause mortality among adults ages 25-44 during the COVID-19 pandemic in the US.  
• Found that COVID-19 has likely become the leading cause of death (surpassing unintentional overdoses) among young adults aged 25-44 in some areas of the US during substantial COVID-19 outbreaks. |

### Infection control / non-pharmaceutical interventions

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
<th>Digest</th>
</tr>
</thead>
</table>
| 23.10.2020       | **EMG: Role of ventilation in controlling SARS-CoV-2 transmission, 30 September 2020** | Gov.uk / Research and analysis | • Paper by Environmental and Modelling group on the role of ventilation.  
• Ventilation is an important factor in mitigating against the risk of far-field (>2m) aerosol transmission, but has no impact on other transmission routes (high confidence). The importance of far-field aerosol transmission is not yet known, but evidence suggests it is a risk in poorly ventilated spaces (medium confidence). |

| 23.10.2020       | **Decrease in Hospitalizations for COVID-19 after Mask Mandates in 1083 U.S. Counties** | medRxiv (non-peer reviewed) / Article | • Aimed to determine if facial mask mandates instituted in U.S. counties over the spring and summer of 2020 were associated with declining severity of infection as measured by the number of hospitalizations for COVID-19.  
• Concluded that facial masking may decrease COVID-19 severity by decreasing the viral inoculum to which individuals are exposed.  
• Mask mandates across 1083 counties in the U.S. in 49 states decreased |
hospitalization rates from COVID-19 even when controlling for other factors that could impact disease severity, including age, testing access, number of cases, and mobility.

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
<th>Digest</th>
</tr>
</thead>
</table>
| 23.10.2020       | **Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study** | Lancet Respiratory Medicine / Article                        | • Aimed to describe the practice of ventilation management and to establish outcomes in invasively ventilated patients with COVID-19 in a single country during the first month of the outbreak.  
• Between Mar 1 and Apr 1, 2020, 553 patients were included in the study.  
• In patients with COVID-19 who were invasively ventilated during the first month of the outbreak in the Netherlands, lung-protective ventilation with low tidal volume and low driving pressure was broadly applied and prone positioning was often used. The applied PEEP varied widely, despite an invariably low respiratory system compliance. |
| 22.10.2020       | **Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)** | BMJ / Research                                               | • Multicentre, randomised controlled trial to investigate effectiveness of convalescent plasma to treat moderate COVID-19 in adults in India.  
• Participants (n=464) were assigned to either: i) convalescent plasma (n=235; two doses of 200 mL, transfused 24 hours apart) with best standard of care (intervention group), or; ii) best standard of care only (n=229) (control group).  
• Findings suggest convalescent plasma was not associated with a reduction in progression to severe covid-19 or all-cause mortality. |
| 15.10.2020       | **Melatonin is significantly associated with survival of intubated COVID-19 patients** | medRxiv (non-peer reviewed) / Article                        | • Retrospective study examined whether mortality following intubation was associated with melatonin exposure in 791 COVID-19 patients (948 intubation periods in total), and 2,981 patients who were not infected with COVID-19 (3,497 intubation periods).  
• Melatonin exposure after intubation was statistically associated with a positive outcome in COVID-19 (demographics and comorbidities adjusted HR: 0.131, 95% CI: 0.76E-02 - 0.223, p-value = 8.19E-14) and non-COVID-19 (demographics and comorbidities adjusted HR: 0.278, 95% CI: 0.142 - 0.542, p-value = 1.72E-04) intubated patients. |
| 21.10.2020       | **Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial** | medRxiv (non-peer reviewed) / Article                        | • Adult COVID-19 patients (n=392) randomised to receive either 500mg nitazoxanide (n=194) or placebo (n=198) for 5 days.  
• At the 5-day study visit, symptom resolution (dry cough, fever, and/or fatigue) did not differ between the nitazoxanide and placebo arms.  
• However, at the 1-week follow-up, 78% in the nitazoxanide arm and 57% in...
Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009).

- Viral load was reduced after nitazoxanide compared to placebo (p=0.006).
- No serious adverse events were observed.

### Vaccine development

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
<th>Digest</th>
</tr>
</thead>
<tbody>
<tr>
<td>26.10.2020</td>
<td><a href="#">Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK</a></td>
<td>European Centre for Disease Prevention and Control / Technical report</td>
<td>This document provides an overview of the key aspects related to the initial phases following the introduction of one or more COVID-19 vaccines in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK). The aim is to support but not define EU policy on COVID-19 vaccination.</td>
</tr>
</tbody>
</table>

### Modelling

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
<th>Digest</th>
</tr>
</thead>
</table>
| 22.10.2020       | [The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries](#) | Lancet Infectious Diseases / Article | Aimed to understand the association of introducing and lifting non-pharmaceutical interventions (NPIs) with the level of transmission of SARS-CoV-2, as measured by the time-varying reproduction number (R), from a broad perspective across 131 countries.  
- Individual NPIs, including school closure, workplace closure, public events ban, ban on gatherings of more than ten people, requirements to stay at home, and internal movement limits, are associated with reduced transmission of SARS-CoV-2, but the effect of introducing and lifting these NPIs is delayed by 1–3 weeks, with this delay being longer when lifting NPIs. |
- Projections of current non-pharmaceutical intervention strategies by state—with social distancing mandates reinstated when a threshold of 8 deaths per million population is exceeded (reference scenario)—suggest that, cumulatively, 511,373 (469,578–578,347) lives could be lost to COVID-19 across US by 28 Feb 2021.  
- Universal mask use (95% mask use in public) could ameliorate worst effects of
epidemic resurgences in many states - by saving an additional 129,574 (85,284–170,867) lives, or an additional 95,814 (60,731–133,077) lives assuming a lesser adoption of mask wearing (85%), when compared to the reference scenario.

### Overviews, comments and editorials

<table>
<thead>
<tr>
<th>Publication Date</th>
<th>Title / URL</th>
<th>Journal / Article type</th>
</tr>
</thead>
<tbody>
<tr>
<td>22.10.2020</td>
<td>Quarterly report on progress to address COVID-19 health inequalities</td>
<td>Gov.uk / Correspondence</td>
</tr>
<tr>
<td>23.10.2020</td>
<td>Consequences of COVID-19 for cancer care - a CRUK perspective</td>
<td>Nat Rev Clin Oncol / Comment</td>
</tr>
<tr>
<td>23.10.2020</td>
<td>Virology, transmission, and pathogenesis of SARS-CoV-2</td>
<td>Bmj / Review</td>
</tr>
<tr>
<td>22.10.2020</td>
<td>Understanding protection from SARS-CoV-2 by studying reinfection</td>
<td>Nat Med / News and views</td>
</tr>
<tr>
<td>25.10.2020</td>
<td>Treating COVID-19: are we missing out the window of opportunity?</td>
<td>Journal of Antimicrobial Chemotherapy / Article</td>
</tr>
<tr>
<td>23.10.2020</td>
<td>Dexamethasone and remdesivir: finding method in the COVID-19 madness</td>
<td>Lancet Microbe / Comment</td>
</tr>
<tr>
<td>23.10.2020</td>
<td>The engines of SARS-CoV-2 spread</td>
<td>Science / Perspective</td>
</tr>
<tr>
<td>22.10.2020</td>
<td>Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts</td>
<td>Bmj / Feature</td>
</tr>
</tbody>
</table>

Produced by the PHE COVID-19 Literature Digest Team

To sign-up, email COVID.LitDigest@phe.gov.uk
A selection of previous digests can be found here

www.gov.uk/phe Follow us on Twitter @PHE_uk
Protecting and improving the nation's health